Form D · Biotechnology
Commense Bio, Inc.
Boulder, CO · CIK 0002135129
Offering snapshot reported Jun 12, 2026 · SEC filing
- Reported sold
- $2.47M Offering amount: $2.67M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 18, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2026 | Initial | $2,470,334 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-587215
Source: Form D, filed Jun 12, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Judith Boice | Director |
| N. Stuart Harris | Director |
| Erik Prentice | Director |
| Joshua Smith | Director |
| Todd Turner | Director, Executive |
| Randall W. Viola | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2805 Wilderness Place, Suite 1000
Boulder, CO, 80301
Boulder, CO, 80301